ICICI Direct: Caplin Point - Strong Latin America Growth Drives Q2 Numbers
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Caplin Point Laboratories Ltd.’s Q2 FY21 revenues grew 18% YoY to Rs 268 crore.
Ebitda margins improved 131 basis points YoY to 32.6% due to higher gross margins partially offset by higher staff costs due to recently acquired subsidiaries.
Sequential margin improvement (up 279 basis points) was on account of a better overall operational performance.
Subsequently, Ebitda grew 22.9% YoY, 22.1% QoQ to Rs 87 crore.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.